Cawston, Helene, Bourhis, Francois, Eriksson, Jennifer, Ruffo, Pierfrancesco, Di'Agostino, Paolo, Turini, Marco, Schwartzberg, Lee and McGuire, Alistair 
ORCID: 0000-0002-5367-9841
(2017)
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.
Drugs in Context, 6.
pp. 1-13.
ISSN 1740-4398
|
Text
- Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (562kB) | Preview |
Abstract
Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patients undergoing treatment with highly or moderately emetogenic chemotherapy (HEC or MEC) in the UK. Scope: A systematic literature review and meta-analysis were undertaken to compare NEPA with currently recommended anti-emetics. Relative effectiveness was estimated over the acute (day 1) and overall treatment (days 1–5) phases, taking complete response (CR, no emesis and no rescue medication) and complete protection (CP, CR and no more than mild nausea [VAS scale <25 mm]) as primary efficacy outcomes. A three-health-state Markov cohort model, including CP, CR and incomplete response (no CR) for HEC and MEC, was constructed. A five-day time horizon and UK NHS perspective were adopted. Transition probabilities were obtained by combining the response rates of CR and CP from NEPA trials and odds ratios from the meta-analysis. Utilities of 0.90, 0.70 and 0.24 were defined for CP, CR and incomplete response, respectively. Costs included medications and management of CINV-related events and were obtained from the British National Formulary and NHS Reference Costs. The expected budgetary impact of NEPA was also evaluated. Findings: In HEC patients, the NEPA strategy was more effective than APPA (quality-adjusted life days [QALDs] of 4.263 versus 4.053; incremental emesis-free and CINV-free days of +0.354 and +0.237, respectively) and was less costly (£80 versus £124), resulting in NEPA being the dominant strategy. In MEC patients, NEPA was cost effective, cumulating in an estimated 0.182 extra QALDs at an incremental cost of £6.65 compared with PA. Conclusion: Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.
| Item Type: | Article |
|---|---|
| Official URL: | http://www.drugsincontext.com/ |
| Additional Information: | © 2017 The Authors © CC BY NC ND 3.0 |
| Divisions: | Social Policy |
| Subjects: | R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine |
| Date Deposited: | 13 Oct 2017 13:12 |
| Last Modified: | 24 Oct 2024 23:24 |
| Funders: | Helsinn Healthcare SA |
| URI: | http://eprints.lse.ac.uk/id/eprint/84649 |
Actions (login required)
 |
View Item |
Download Statistics
Download Statistics